JP2020532496A - 高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法 - Google Patents

高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法 Download PDF

Info

Publication number
JP2020532496A
JP2020532496A JP2020504380A JP2020504380A JP2020532496A JP 2020532496 A JP2020532496 A JP 2020532496A JP 2020504380 A JP2020504380 A JP 2020504380A JP 2020504380 A JP2020504380 A JP 2020504380A JP 2020532496 A JP2020532496 A JP 2020532496A
Authority
JP
Japan
Prior art keywords
ipr
high affinity
selective binding
peptide conjugate
binding ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532496A5 (enExample
Inventor
チャン，ユンゲ
ツェン ヤン，リャン
ツェン ヤン，リャン
Original Assignee
メインライン バイオサイエンシズ
メインライン バイオサイエンシズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メインライン バイオサイエンシズ, メインライン バイオサイエンシズ filed Critical メインライン バイオサイエンシズ
Publication of JP2020532496A publication Critical patent/JP2020532496A/ja
Publication of JP2020532496A5 publication Critical patent/JP2020532496A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020504380A 2017-09-05 2018-02-17 高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法 Pending JP2020532496A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
US62/554,354 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Publications (2)

Publication Number Publication Date
JP2020532496A true JP2020532496A (ja) 2020-11-12
JP2020532496A5 JP2020532496A5 (enExample) 2021-02-04

Family

ID=65635072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504380A Pending JP2020532496A (ja) 2017-09-05 2018-02-17 高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法

Country Status (6)

Country Link
EP (1) EP3679053A4 (enExample)
JP (1) JP2020532496A (enExample)
KR (2) KR20230145543A (enExample)
CN (1) CN111183146A (enExample)
CA (1) CA3065086A1 (enExample)
WO (1) WO2019050564A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
CN115003684A (zh) * 2020-01-26 2022-09-02 主线生物科学有限公司 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法
CN118852348A (zh) 2022-02-11 2024-10-29 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
EP4511384A1 (en) * 2022-04-20 2025-02-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
CN116023438B (zh) * 2023-02-06 2025-07-11 中国药科大学 一种cxcr4靶向多肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529957A (ja) * 2007-05-30 2010-09-02 イーライ リリー アンド カンパニー 環状ペプチドｃｘｃｒ４アンタゴニスト
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5308829B2 (ja) * 2006-02-27 2013-10-09 テクニッシュ ユニべルシタット ミュンヘン 癌の画像化および処置
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
IN2014KN02752A (enExample) * 2012-06-06 2015-05-08 Polyphor Ag
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529957A (ja) * 2007-05-30 2010-09-02 イーライ リリー アンド カンパニー 環状ペプチドｃｘｃｒ４アンタゴニスト
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, VOL.20, PP.2661-2668, JPN6021040906, ISSN: 0004862117 *
生化学, 2010, VOL.82, NO.6, PP.515-523, JPN6021040904, ISSN: 0004862116 *

Also Published As

Publication number Publication date
CN111183146A (zh) 2020-05-19
CA3065086A1 (en) 2019-03-14
KR20200043970A (ko) 2020-04-28
EP3679053A4 (en) 2021-10-27
WO2019050564A1 (en) 2019-03-14
KR20230145543A (ko) 2023-10-17
EP3679053A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
JP2020532496A (ja) 高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法
JP7664158B2 (ja) トランスフェリン受容体標的ペプチド
KR100668546B1 (ko) 수용체에 결합하는 펩티드 및 화합물
JP5358564B2 (ja) 環状ペプチドｃｘｃｒ４アンタゴニスト
CA2945945C (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US20150125491A1 (en) Immunomodulating Cyclic Compounds
JP7100639B2 (ja) Ｃｘｃｒ４アンタゴニストおよび使用方法
US11883501B2 (en) Selective CXCR4 binding peptide conjugate and methods for making and using the same
US20230099200A1 (en) Radiolabeled peptides for non-invasive diagnosis and treatment of cxcr4 expressing tumors
JP2014513066A (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
EP3122369B1 (en) Cyclic prosaposin peptides and uses thereof
US10301352B2 (en) Peptidomimetics with antiangiogenic activity
WO2021150258A1 (en) Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
CN113024635A (zh) 一类订书肽化合物及其药物组合物的用途
WO2025043563A1 (zh) 一种靶向生长抑素受体的肽、偶联药物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220704

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220726

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220727

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220902

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220906